NewKerala.com

India Tightens Watch on GLP-1 Weight-Loss Drugs Amid Safety, Misuse Fears

Indian drug regulators are enhancing surveillance of GLP-1 receptor agonists used for weight loss and diabetes, driven by rising demand and the impending arrival of cheaper generic versions. The Drug Controller General of India has intensified inspections, auditing 49 entities like online pharmacies and clinics for violations including sales without prescriptions. The government has issued warnings and notices, stating that only qualified medical specialists are authorized to prescribe these medicines. This regulatory push aims to address safety concerns and prevent misuse amid potential side effects like pancreatitis and kidney injury.

Key Points: India Steps Up Surveillance of GLP-1 Drugs, Generic Weight-Loss Therapies

  • Strengthened adverse event monitoring
  • Crackdown on unauthorized sales & misleading ads
  • 49 entities inspected nationwide
  • Only specialists authorized to prescribe
2 min read

India tightens watch on GLP-1 drugs amid safety and misuse concerns

India intensifies oversight of GLP-1 weight-loss drugs, inspects 49 entities, and warns against misuse as cheaper generics near market. Read more.

"continued non-compliance could lead to licence cancellations, financial penalties and legal action - Government warning"

New Delhi, April 4

India's drug regulators are stepping up oversight of fast-growing weight-loss and diabetes therapies, particularly GLP-1 receptor agonists, amid rising demand and the anticipated entry of cheaper generic versions into the domestic market.

The move comes as the Indian Pharmacopoeia Commission (IPC), which functions under the Ministry of Health, has been tasked with systematically collecting and analysing adverse event reports linked to these drugs.

The initiative aims to strengthen post-marketing surveillance and ensure that any safety concerns are quickly identified and addressed.

Officials indicated that the step is part of a broader regulatory push to keep pace with the rapid uptake of these therapies, especially as affordability improves.

With the patent expiry of semaglutide, a key ingredient in popular weight-loss treatments, more low-cost generic alternatives are expected to hit the market, potentially expanding access but also raising the risk of misuse.

The tightening of surveillance builds on recent enforcement actions led by the Drug Controller General of India (DCGI), which has intensified inspections to curb unauthorised sale and promotion of GLP-1 drugs.

In recent weeks, authorities audited 49 entities across the country, including online pharmacy warehouses, wholesalers, retailers and weight-loss clinics.

These inspections, conducted across multiple regions, focused on identifying violations such as sale without prescription, improper prescribing practices and misleading marketing.

Notices have been issued to violators, with the government warning that continued non-compliance could lead to licence cancellations, financial penalties and legal action.

The Centre has also made it clear that only qualified specialists, including endocrinologists, internal medicine experts and cardiologists, are authorised to prescribe these medicines.

Earlier, on March 10, the government directed manufacturers to halt misleading advertisements and any promotions that could encourage unsupervised use.

GLP-1 receptor agonists, widely used to treat type 2 diabetes and increasingly prescribed for weight loss, work by stimulating insulin secretion and reducing appetite by slowing gastric emptying.

However, health authorities have flagged potential side effects ranging from nausea and vomiting to more serious risks such as pancreatitis, kidney injury and bowel obstruction.

- IANS

Share this article:

Reader Comments

R
Rohit P
Good move! With cheaper generics coming, these drugs will become accessible to the masses. But our medical infrastructure is already strained. We need more awareness campaigns so people don't self-prescribe based on WhatsApp forwards. Safety first.
A
Aman W
While I support the intent, I hope this doesn't create unnecessary red tape for genuine patients who need these medicines for diabetes management. The focus should be on punishing the bad actors—the clinics and online pharmacies selling without prescription—not making it harder for doctors to treat.
S
Sarah B
The part about only qualified specialists being allowed to prescribe is key. In smaller towns, sometimes general practitioners prescribe everything. Pancreatitis and kidney injury are no joke. This surveillance system needs to be robust and transparent.
V
Vikram M
Finally! The online sale of these drugs was getting out of hand. You could just add it to cart like shampoo. Health is not e-commerce. The DCGI raids are a strong message. Hope they keep the pressure on. 🇮🇳
K
Kavya N
As someone whose relative uses this for diabetes, the cost is a huge burden. Cheaper generics will be a blessing. But yes, with lower cost comes greater responsibility from both the government and us citizens to use them wisely. Let's not turn a solution into a problem.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50